Updates - Page 3
NB staff supports Motor Neurone Disease Charity
Having become engaged (now married!) in the summer of 2021, Will’s thoughts turned to arrangements for his stag party. Rather than take the traditional route Will hatched a plan…
Read update
First podocyte toxicity assay now commercially available
Damage to the glomerular filtration barrier (GFB) results in protein leakage from the plasma into the urine, so called proteinuria, and is associated with loss of kidney function, which…
Read update
How a glomerulus in vitro model can accelerate drug development
The glomerulus is the part of the kidney involved in the filtration of solutes and waste from the blood. Damage to the glomerulus by diabetes mellitus, hypertension, glomerulonephritis, or…
Read update
New Product Launched – aProximate™ Assay-Ready Plates for transporter studies
aProximate™ Assay-ready plates contain freshly isolated primary human proximal tubule cells (PTCs). The plates are provided in an easy to use 24-well Transwell® format. Visit our product page…
Read update
Gene therapy vectors: Preclinical testing with retinal organoids
Adeno Associated Virus (AAV) vectors have emerged as the most successful retinal gene therapy vectors following the FDA approval of Luxturna in 2017. This new gene therapy product is…
Read update
Organ-on-a-chip: the next generation tool for drug development?
Organ-on-a-chip (OoC) or Microphysiological systems (MPS) are microfluidic devices providing a controlled microenvironment for miniaturised tissues mimicking physiological architecture and function of human tissues and organs. The application of dynamic…
Read update
Retinal Organoids for Drug Discovery
Retinal diseases have been at the forefront of gene and cell therapy over the last 30 years with conditions such as macular degeneration and Stargardt disease likely to be…
Read update
Why is an in vitro model of the glomerulus desperately needed?
In most cases, once the kidney’s function is limited, the only treatment options are dialysis and kidney transplant. The absence of effective drugs to treat kidney disease is partly…
Read update
How to reduce drug attrition during drug development?
There are two main causes of drug attrition: safety and efficacy, and in both instances, the common denominator is the inadequacy of current preclinical models to predict outcomes in…
Read update
Dr Kathryn Garner, Head of Kidney Development at NB
As she narrates her story, you have the impression that you have made the journey with her, her words becoming rich images in…
Read update
iPSC-derived Retinal Organoids: an alternative in vitro model for drug discovery
What retinal models are available for drug development? Animal models are the most frequently used for investigating safety and efficacy of ophthalmic drugs. However, due to several key physiological differences,…
Read update
In vitro models for chronic kidney disease (CKD)
Phosphate balance is central to many metabolic pathways, and the kidneys play a key role in the reabsorption and excretion of phosphate to achieve this balance. In CKD, however,…
Read update
